Barrow, Hanley, Mewhinney & Strauss
PCRX icon

Barrow, Hanley, Mewhinney & Strauss’s Pacira BioSciences PCRX Stock Holding History

Barrow, Hanley, Mewhinney & Strauss’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-60
Closed -$1.13K – 345
2024
Q4 		$1.13K Hold
60
– – ﹤0.01% 301
2024
Q3 		$903 Buy
+60
New +$1.03K ﹤0.01% 311

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss's PCRX Position: Q1 2025 in Review

Barrow, Hanley, Mewhinney & Strauss sold out of Pacira BioSciences (PCRX) in Q1 2025, closing a stake of 60 shares — an estimated $1.13K sold.

Barrow, Hanley, Mewhinney & Strauss first reported a position in PCRX in Q3 2024 and held it in 2 quarters. The position peaked at $1.13K in Q4 2024. 235 funds tracked by Wall St. Rank hold PCRX as of Q1 2025.

  • Barrow, Hanley, Mewhinney & Strauss reported no remaining Pacira BioSciences position as of Q1 2025 after selling out during the quarter.
  • Barrow, Hanley, Mewhinney & Strauss sold 60 Pacira BioSciences shares in Q1 2025, an estimated $1.13K.
  • Barrow, Hanley, Mewhinney & Strauss first reported a position in Pacira BioSciences in Q3 2024 and held it in 2 quarters.
  • Barrow, Hanley, Mewhinney & Strauss's Pacira BioSciences position peaked at $1.13K in Q4 2024.
  • 235 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2025.

Based on Barrow, Hanley, Mewhinney & Strauss's 13F filing for Q1 2025, filed 12 May 2025.